-
2D Versus 3D Models for Cancer Radiosensitizer Discovery
2026-08-21
This 2025 Acta Oncologica study systematically compares DNA-PKcs, ATR, PARP, and IAP pathway inhibitors in matched 2D and 3D lung cancer models. Its central contribution is showing that 2D assays often identify similar radiosensitization patterns, while 3D extracellular-matrix cultures reveal additional context-dependent responses useful for preclinical prioritization.
-
PORCN Inhibition in Sclerosteosis: LGK-974 Study
2026-08-20
Dreyer and colleagues evaluate PORCN inhibition as a pharmacological strategy for sclerosteosis, an ultra-rare high-bone-mass disorder caused by loss of functional sclerostin. Their osteoblast and Sost-deficient mouse experiments show that LGK974 suppresses excessive Wnt activity and reduces selected skeletal overgrowth features without measurably impairing osteoclast resorption.
-
Dabigatran etexilate: Oral Direct Thrombin Inhibition
2026-08-20
The Blommel and Blommel review established dabigatran etexilate as an important oral direct thrombin inhibitor and examined its pharmacology, pharmacokinetics, clinical efficacy, safety, and therapeutic positioning. Its central contribution was to connect a reversible, rapidly acting thrombin inhibition mechanism with an orally absorbed prodrug that offered more predictable anticoagulation than conventional vitamin K antagonist therapy, while also emphasizing renal function and bleeding risk as critical constraints.
-
rTMS, GABAergic Signalling, and Aβ Clearance
2026-08-19
This study links repetitive transcranial magnetic stimulation (rTMS) to cognitive recovery in 5xFAD mice through a GABAergic neuron–microglia Cx3cl1–Cx3cr1 signalling axis. Its integrated single-cell, pathological, cellular, and behavioral analyses suggest that rTMS may improve amyloid clearance by coordinating neuronal signalling with microglial phagocytosis, while also highlighting the need for causal and translational validation.
-
Phosphatase Inhibitor Cocktail 2: Canine MGT Workflows
2026-08-19
Learn how to integrate Phosphatase Inhibitor Cocktail 2 into canine mammary tumor cell workflows for more reliable phospho-signaling measurements. Practical guidance covers lysate preparation, Western blotting, co-immunoprecipitation, kinase assays, troubleshooting, and pathway-focused experiments.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-08-18
Phalloidin (SKU B7678) is a high-affinity F-actin probe for preserving and examining filament organization in fixed or permeabilized samples. It is appropriate for endpoint cytoskeleton visualization, but not for live-cell imaging or experiments requiring reversible actin binding and undisturbed cytoskeletal dynamics.
-
Perospirone in Receptor and Kv1.5 Research
2026-08-18
Perospirone (SM-9018 free base) supports receptor-centered schizophrenia research while enabling a complementary investigation of vascular Kv1.5 channel modulation. This workflow-focused guide explains how to connect serotonergic and dopaminergic signaling assays with electrophysiology without overstating early translational evidence.
-
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-08-17
A 2025 European Journal of Cell Biology study established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be cryopreserved, retained differentiation capacity, and produced intestinal epithelial cells with metabolism and transporter functions relevant to oral drug pharmacokinetics.
-
Genotyping Kit: From Sample to Mechanism
2026-08-17
The Genotyping Kit for target alleles connects rapid single-tube DNA preparation with defensible PCR-based genotype interpretation. This article shows how insights from an NR1I3–E-cadherin colitis study can guide assay controls, sample selection, and mechanistic validation across molecular biology workflows.
-
3-Deazaneplanocin (DZNep): Mechanism to Translation
2026-08-16
3-Deazaneplanocin (DZNep) is more than an EZH2-associated research tool: it is a mechanistically broad epigenetic perturbation strategy. This article examines how SAHH inhibition, EZH2 suppression, tumor-cell state, experimental design, and disease context should be integrated to generate translationally useful evidence.
-
Multianimal MRI for Pancreatic Tumor Monitoring
2026-08-15
Kempinska and colleagues describe a four-chamber MRI workflow that enables high-resolution imaging of up to four pancreatic cancer-bearing mice in one acquisition session. Applied to the clinically relevant KPC model, the protocol supports tumor detection, longitudinal measurement, trial enrollment, and proof-of-concept assessment of gemcitabine while reducing imaging time and resource demands.
-
Renal Blood Flow, Norepinephrine, and Sepsis
2026-08-14
This study examined how potassium-channel blockade changes renal vascular responses to norepinephrine and phenylephrine in septic rats. Its central finding is that blocking Kir6.1 or KCa1.1 channels may not alter basal renal blood flow, yet can markedly worsen pressor-associated renal hypoperfusion, revealing a context-dependent protective role for vascular potassium channels during sepsis.
-
XYD113: A Selective GSPT1 Degrader for MYC-Driven Cancer
2026-08-14
The reference study presents XYD113 as a potent molecular glue degrader that selectively eliminates GSPT1 through a CRBN-dependent ubiquitin–proteasome mechanism. Its activity across MYC-overexpressing cancer models, favorable selectivity profile, and preliminary oral xenograft efficacy support further investigation while leaving important clinical and mechanistic questions unresolved.
-
Fucoidan: Designing Mechanism-Resolved Cancer Assays
2026-08-13
Fucoidan is a Sulfated α-L-Fucan with anticancer activity that should be evaluated through layered, mechanism-resolved assays rather than viability alone. This guide connects caveolin-1, apoptosis, migration, and immune context to practical breast cancer research decisions.
-
CHK1 Inhibition in Breast Cancer: ER/PR-Dependent Effects
2026-08-13
The reference study shows that CHK1 inhibition is not uniformly useful across breast cancer subtypes: it enhances adriamycin sensitivity in ER-/PR-/HER2- disease but has limited chemosensitizing value in ER+/PR+/HER2- cells. Its most important contribution is a receptor-context framework linking CHK1 inhibition to distinct cell-cycle, transcriptional, and apoptotic mechanisms.